Hôpital Saint Louis APHP
Welcome,         Profile    Billing    Logout  
 8 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lebbe, Céleste
IGNYTE, NCT03767348 / 2016-004548-12: Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Hourglass Jan 2024 - Mar 2024 : Data from IGNYTE trial in combination with Opdivo for 2L melanoma
Checkmark From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Nov 2020 - Nov 2020: From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Checkmark Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Nov 2019 - Nov 2019: Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Recruiting
2
340
Europe, US
RP1, nivolumab, Opdivo
Replimune Inc.
Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
11/24
11/24
MELpreserv, NCT05429138: Ovarian Reserve and Semen Parameters Evolution During Adjuvant Therapy in Melanoma

Recruiting
N/A
80
Europe
biological sampling
Assistance Publique Hopitaux De Marseille
Melanoma
12/26
12/26
Doucet, Ludovic
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
Optim-UCPVax, NCT04263051: Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer

Active, not recruiting
2
111
Europe
UCPVax + Nivolumab, standard chemotherapy
Centre Hospitalier Universitaire de Besancon, Bristol-Myers Squibb, Fondation ARC
Advanced Non-small Cell Lung Cancer
09/23
09/25
PersoMed-I, NCT04402073 / 2020-003063-26: Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma

Active, not recruiting
2
20
Europe, RoW
Sonidegib, Cisplatin, Lomustine, Vincristine, radiotherapy
European Organisation for Research and Treatment of Cancer - EORTC, EORTC-BTG, Sunpharmaceuticals
Medulloblastoma
04/25
04/25
TNG908-C101, NCT05275478: Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Active, not recruiting
1/2
192
Europe, US
TNG908
Tango Therapeutics, Inc.
Locally Advanced Solid Tumor
04/25
09/25
Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Recruiting
1/2
374
Europe, Canada, Japan, US, RoW
Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil
Takeda, Takeda Development Center Americas, Inc. (TDC Americas)
Solid Neoplasms
01/26
01/26

Download Options